BIOKIN PHARMACEUTICAL(688506)2024-11-20 09:07Group 1: R&D Investment and Progress - The company invested 932 million CNY in R&D during the first three quarters of 2024, representing an increase of 80.34% compared to the same period last year [4] - As of now, the company has advanced 3 drugs to the III phase of clinical research, including 2 ADC drugs and 1 bispecific antibody drug [4] - The company is developing 10 early-stage core clinical assets, including 5 ADC drugs, 4 GNC drugs, and 1 bispecific antibody drug [4] Group 2: Revenue Growth - The company achieved a revenue of 5.663 billion CNY in the first three quarters of 2024, marking a significant increase of 1,399.22% year-on-year [6] - The primary reason for the substantial revenue growth is an irrevocable and non-deductible upfront payment of 800 million USD received from global pharmaceutical partner BMS based on the BL-B01D1 collaboration agreement [6] Group 3: Future Plans and Dividend Policy - The company has established a profit distribution mechanism in its articles of association, outlining the decision-making process for profit distribution and principles for adjustments [6] - Any future dividend plans will be disclosed in accordance with relevant regulations [6]